跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TDP-43
首页
药物
TDP-43
TDP-43
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
TDP-43 MITOCHONDRIAL LOCALIZATION INHIBITOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
EP 3440094 B1
申请人: UNIV CASE WESTERN RESERVE
优先权: 2016
CN
EP
US
WO
8 件公开
ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF
EP 3972692 A1
申请人: AC IMMUNE SA
优先权: 2019
CN
EP
US
WO
6 件公开
EP 4676596 A1
申请人: AC IMMUNE SA
优先权: 2023
CN
EP
WO
3 件公开
MODELING TDP-43 PROTEINOPATHY
EP 3990475 A1
申请人: REGENERON PHARMA
优先权: 2019
CN
EP
US
WO
6 件公开
TDP-43 SPECIFIC BINDING MOLECULES
EP 3964524 A1
申请人: BIOGEN INT NEUROSCIENCE GMBH
优先权: 2011
CN
EP
US
6 件公开
MODULATORS OF TDP-43
EP 3942038 A1
申请人: ALTERON THERAPEUTICS INC
优先权: 2019
CN
EP
US
WO
5 件公开
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES
EP 4143215 A2
申请人: SOLA BIOSCIENCES LLC
优先权: 2020
CN
EP
US
WO
5 件公开
PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY
EP 4408470 A4
申请人: UNIV UTAH RES FOUND
优先权: 2021
EP
US
WO
5 件公开
US 20260234229 A1
申请人: UNIV UTAH RES FOUND
优先权: 2025
US
Sequences associated with TDP-43 proteinopathies and methods of using the same
US 8889597 B2
申请人: CAIRNS NIGEL J
优先权: 2009
US
5 件公开
Anti-TDP-43 Binding Molecules
US 20260043816 A1
申请人: AC IMMUNE SA
优先权: 2022
CN
EP
US
WO
4 件公开
AGGREGATION-RESISTANT VARIANTS OF TDP-43
EP 4565603 A1
申请人: REGENERON PHARMA
优先权: 2022
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈